Program
ivonescimab
Also written as “AK112”, “Ivonescimab Injection” and “Ivonescimab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms · Small Cell Lung Carcinoma, led by 5 companies.
Drug pageIvonescimab: every studyMany companies study it; this page follows only the 48 they lead. All 147 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 3930 open or running | phase 3since Dec 21, 2021 | Aug 5, 2019 | Dec 2026phase 2 · NCT05689853 |
| Summit Therapeuticsits history only | 66 open or running | phase 3since Jun 1, 2023 | Jun 1, 2023 | Apr 2028phase 3 · NCT06767514 |
| GlaxoSmithKlineits history only | 11 open or running | phase 2since May 15, 2026 | May 15, 2026 | Jun 22, 2029phase 2 · NCT07602855 |
| Multitude Therapeuticsits history only | 11 open or running | phase 2since May 10, 2026 | May 10, 2026 | May 30, 2027phase 2 · NCT07590531 |
| Shanghai Allink Biotherapeuticsits history only | 11 open or running | phase 2since Jul 29, 2026 | Jul 29, 2026 | Dec 31, 2027phase 2 · NCT07742956 |
Also a collaborator on its studies: Shanghai Virogin Biotech.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseSummit Therapeutics licensed it from Akeso, for the US, Canada, Europe and Japan.Announced Dec 6, 2022 · Source: Summit Therapeutics (8-K exhibit), Dec 6, 2022
How GlaxoSmithKline, Multitude Therapeutics and Shanghai Allink Biotherapeutics relate to it is not in the registry or these sources.
History and studies of Akeso only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 22 earlier studies, Aug 5, 2019 to Jul 28, 2024.
- Jul 28, 2021Named ivonescimabINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AK112
- Dec 6, 2022Summit Therapeutics licensed it from AkesoLicenseThe US, Canada, Europe and Japan · announced · Summit Therapeutics (8-K exhibit)
- Aug 15, 2024Phase 2 study in Ovarian NeoplasmsNCT06560112 · 172 planned · China
- Aug 29, 2024Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06601335 · 510 planned · China
- Sep 8, 2024Phase 3 study in Biliary Tract NeoplasmsNCT06591520 · 682 enrolled · China
- Oct 16, 2024Phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055 · 110 enrolled · China
- Nov 11, 2024Phase 2 study in Platinum-sensitive Ovarian CancerNCT06686030 · 150 planned · China
- Jan 8, 2025Phase 3 study in Triple Negative Breast NeoplasmsNCT06767527 · 416 planned · China
- Mar 10, 2025Phase 2 study in Biliary Tract NeoplasmsNCT06938321 · 135 planned · China
- Apr 8, 20253 phase 3 studiesNCT06928389, NCT06951503, NCT06953999
- May 25, 2025Phase 3 study in Small Cell Lung CarcinomaNCT07010263 · 560 planned · China
- Aug 3, 20252 phase 2 studiesNCT07114315, NCT07158840
- Sep 29, 2025Phase 2 study in Small Cell Lung CarcinomaNCT07245446 · 180 planned · China
- Dec 24, 2025Phase 2 study in Colorectal Cancer With Hepatic MetastasesNCT07357220 · 72 planned · China
- Jan 6, 2026Phase 1 study in Healthy Male SubjectsNCT07340476 · 108 enrolled · China
- Jun 21, 2026Phase 2 study in Advanced Non Small Cell Lung Cancer (NSCLC)NCT07669779 · 348 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT06767527
- Dec 2026Primary completion: phase 2 study in Solid Tumor, AdultNCT05689853
- Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055
- Dec 30, 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsNCT05227664
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 39 Akeso leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07669779Advanced Non Small Cell Lung Cancer (NSCLC) · China | 2 | Recruiting | Aug 30, 2027 | 348 |
| NCT07340476Healthy Male Subjects · China | 1 | Active, not recruiting | Apr 10, 2026 | 108 |
| NCT07357220Colorectal Cancer With Hepatic Metastases · China | 2 | Not yet recruiting | Feb 28, 2027 | 72 |
| NCT07245446Small Cell Lung Carcinoma · China | 2 | Recruiting | Dec 2027 | 180 |
| NCT07158840Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Sep 2028 | 60 |
| NCT07114315Pancreatic Neoplasms · China | 2 | Recruiting | Aug 2027 | 160 |
| NCT07010263Small Cell Lung Carcinoma · China | 3 | Recruiting | Dec 31, 2028 | 560 |
| NCT06953999Pancreatic Neoplasms · China | 3 | Recruiting | May 14, 2027 | 999 |
| NCT06951503Colorectal Adenocarcinoma · China | 3 | Recruiting | Jan 13, 2027 | 560 |
| NCT06928389Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | May 2027 | 536 |
| NCT06938321Biliary Tract Neoplasms · China | 2 | Recruiting | May 2027 | 135 |
| NCT06767527Triple Negative Breast Neoplasms · China | 3 | Recruiting | Dec 2026 | 416 |
| NCT06686030Platinum-sensitive Ovarian Cancer · China | 2 | Recruiting | Oct 2027 | 150 |
| NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China | 2 | Active, not recruiting | Dec 30, 2026 | 110 |
| NCT06591520Biliary Tract Neoplasms · China | 3 | Active, not recruiting | Oct 2026 | 682 |
| NCT06601335Squamous Cell Carcinoma of Head and Neck · China | 3 | Recruiting | Jan 2027 | 510 |
| NCT06560112Ovarian Neoplasms · China | 2 | Recruiting | May 1, 2026 | 172 |
| NCT06530251Carcinoma, Hepatocellular · China | 2 | Recruiting | Jun 2026 | 280 |
| NCT05951608Advanced Solid Tumors · China | 2 | Active, not recruiting | May 1, 2026 | 216 |
| NCT05904379Advanced Non-small-cell Lung Cancer · China | 2 | Active, not recruiting | Jun 30, 2026 | 233 |
| NCT05846867Colorectal Neoplasms · China | 2 | Active, not recruiting | May 8, 2026 | 170 |
| NCT05840016Advanced Squamous Non Small Cell Lung Cancer · China | 3 | Active, not recruiting | Feb 28, 2025 | 532 |
| NCT05689853Solid Tumor, Adult · China | 2 | Recruiting | Dec 2026 | 87 |
| NCT05636267NSCLC · China | 2 | Terminated | Feb 24, 2025 | 59 |
| NCT05499390Advanced Non-small-cell Lung Cancer · China | 3 | Active, not recruiting | Jan 29, 2024 | 398 |
| NCT05432492Carcinoma, Hepatocellular · China | 2 | Completed | Apr 30, 2025 | 40 |
| NCT05382442Colorectal Neoplasms · United States, China | 2 | Active, not recruiting | May 15, 2026 | 254 |
| NCT05229497Advanced Malignant Tumors · China | 2 | Active, not recruiting | Dec 31, 2026 | 154 |
| NCT05227664Triple Negative Breast Neoplasms · China | 2 | Active, not recruiting | Dec 30, 2026 | 120 |
| NCT05247684Resectable Non-small Cell Lung Cancer · China | 2 | Active, not recruiting | Aug 18, 2025 | 90 |
| NCT05214482Advanced Malignant Tumors · China | 2 | Completed | Nov 20, 2025 | 154 |
| NCT05184712Non-Squamous Non-small Cell Lung Cancer · China | 3 | Active, not recruiting | Mar 10, 2023 | 322 |
| NCT05116007SCLC, Extensive Stage · China | 1 | Completed | Dec 4, 2023 | 35 |
| NCT04999605Ovarian Neoplasms · China | 2 | Terminated | Jun 10, 2022 | 8 |
| NCT04900363Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Jun 28, 2024 | 108 |
| NCT04870177Neoplasm Metastasis · China | 2 | Completed | May 10, 2024 | 53 |
| NCT04736823NSCLC · China | 2 | Active, not recruiting | Jul 2026 | 265 |
| NCT04597541Solid Tumor, Adult · China | 2 | Completed | Mar 31, 2022 | 59 |
| NCT04047290Neoplasms · Australia | 1 | Completed | Feb 27, 2024 | 80 |
How it is read
Names in the registry
- “AK112”, 27 entries
- “Ivonescimab Injection”, 3 entries
- “Ivonescimab”, 3 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “AK112 Injection”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 14 studies
- Colorectal Neoplasms, 4 studies
- Ovarian Neoplasms, 3 studies
- Triple Negative Breast Neoplasms, 2 studies
- Small Cell Lung Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.